Circulating growth factors data associated with insulin secretagogue use in women with incident breast cancer.

Autor:	Wintrob ZA; State University of New York at Buffalo, Dept. of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, United States., Hammel JP; Cleveland Clinic, Dept. of Biostatistics and Epidemiology, 9500 Euclid Ave., Cleveland, OH 44195, United States., Nimako GK; State University of New York at Buffalo, Dept. of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, United States., Gaile DP; State University of New York at Buffalo, Dept. of Biostatistics, 718 Kimball Tower, Buffalo, NY 14214, United States., Forrest A; The UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Campus Box 7569, Chapel Hill, NC 27599, United States., Ceacareanu AC; Roswell Park Cancer Institute, Dept. of Pharmacy Services, Elm & Carlton Streets, Buffalo, NY 14263, United States.
Jazyk:	angličtina
Zdroj:	Data in brief [Data Brief] 2017 Feb 22; Vol. 11, pp. 459-468. Date of Electronic Publication: 2017 Feb 22 (Print Publication: 2017).
DOI:	10.1016/j.dib.2017.02.038
Abstrakt:	Oral drugs stimulating insulin production may impact growth factor levels. The data presented shows the relationship between pre-existing insulin secretagogues use, growth factor profiles at the time of breast cancer diagnosis and subsequent cancer outcomes in women diagnosed with breast cancer and type 2 diabetes mellitus. A Pearson correlation analysis evaluating the relationship between growth factors stratified by diabetes pharmacotherapy and controls is also provided.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu